Name: 글로벌 시장 동향
SKU: PH7474
Availability: InStock

보고서 요약(국문)

개요
전 세계 만성 알레르기 비염 치료제 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
만성 비염은 임상적으로 코막힘, 재채기, 가려움증 또는 콧물 등의 증상이 1년 중 대부분의 날에 1시간 이상 지속되는 코의 염증성 질환으로 정의됩니다. 비염은 일반적으로 1차 진료 및 2차 진료 의사에 의해 관리됩니다. 대부분의 경우 1차 진료에서 진단 및 치료가 가능하지만, 환자가 치료에 반응하지 않거나 다른 질환이 의심되는 경우에는 2차 진료로 의뢰하는 경우가 많습니다.
시장 동향: 동인 및 제약 요인
알레르기 비염 유병률 증가
전 세계적인 질병인 알레르기 비염(AR)은 전 세계적으로 많은 사람들에게 영향을 미칩니다. 알레르기 비염은 코에 영향을 미치는 여러 증상이 복합적으로 나타나는 질환입니다. 이러한 증상은 사람들이 먼지, 동물 비듬 또는 꽃가루와 같이 알레르기를 유발하는 물질을 흡입할 때 발생합니다.
알레르기성 비염과 천식의 증가가 비교적 빠르게 나타났기 때문에 유전적 요인의 변화가 알레르기 질환 증가의 근본적인 원인일 가능성은 낮습니다. 대신, 여러 환경적 요인이 작용했을 수 있습니다. 이러한 요인에는 위생 개선, 대부분의 기생충 감염 박멸, 가정 난방 및 환기 시스템의 변화, 그리고 생활 방식 변화로 인한 신체 활동 감소 및 식단 변화 등이 포함됩니다.
알레르기성 비염 유병률 증가는 예측 기간 동안 식염수 스프레이 시장 성장을 이끄는 중요한 요인 중 하나입니다. 예를 들어, 미국 국립 의학 도서관(National Library of Medicine) 2023년판에 발표된 논문에 따르면, 알레르기성 비염 유병률은 2017년에서 2022년 사이에 1.83%에서 9.23% 사이였습니다. 코로나19 팬데믹 이전과 이후에는 21.38%에서 70.22%로 크게 감소했습니다. 6세에서 18세 사이의 연령층에서는 남성이 여성보다 더 많이 발병했습니다. 따라서 위의 요인들은 예측 기간 동안 시장 성장을 견인하는 데 도움이 됩니다.
또한, 보다 효과적인 제품 및 제형 개발을 위한 광범위한 연구 개발 활동, 환경 조건의 변화, 오염 증가, 환자 수 증가, 생활 방식의 변화 등이 만성 알레르기 비염 시장의 주요 성장 동력으로 작용하고 있습니다.
시장 동향: 제약 요인
알레르기 비염은 수면 장애, 피로, 과민성, 우울증, 집중력 저하 등을 유발할 수 있는 심각한 질환입니다. 치료하지 않고 방치하면 만성화되어 코 염증, 부비동염, 중이염, 수면 무호흡증, 상기도 감염, 치과 문제, 유스타키오관 기능 장애와 같은 합병증을 유발할 수 있습니다. 또한 기존 천식 환자의 경우 천식 발병 위험 증가, 증상 악화, 천식 조절 어려움과도 관련이 있습니다.

시장 세분화 분석
전 세계 만성 알레르기 비염 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 종류별 시장 세분화에서 항히스타민제는 만성 알레르기 비염 치료제 시장 점유율의 약 41.7%를 차지했습니다.
항히스타민제는 약 41.7%의 시장 점유율을 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 항히스타민제는 히스타민 매개 질환을 치료하는 약물 종류입니다. 히스타민 수용체에는 H-1 수용체와 H-2 수용체의 두 가지 주요 유형이 있습니다. H-1 수용체에 결합하는 항히스타민제는 일반적으로 알레르기 및 알레르기 비염 치료에 사용됩니다.
예를 들어, 2021년 6월 미국 식품의약국(FDA)은 부분 처방에서 비처방으로의 전환이라는 절차를 통해 비처방용 비강 항히스타민제를 승인했습니다. 미국 식품의약국(FDA)은 계절성 및 만성 알레르기 비염(일반적으로 알레르기라고 함) 치료를 위해 6세 이상 성인 및 어린이에게 아스테프로(아젤라스틴 염산염 비강 스프레이, 0.15%)를 승인했습니다.
지역 분석
유럽은 2022년 시장 점유율의 약 31.4%를 차지했습니다.
유럽은 만성 알레르기 비염 유병률 증가, 신약 출시, 연구 개발 투자 증가, 시장 내 주요 업체들의 입지 강화, 주요 업체와의 협력 및 인수 합병 등 여러 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 31.4%를 차지할 것으로 예상됩니다.
예를 들어, 글렌마크 파마는 2021년 4월 유럽연합(EU) 17개국에서 비강 스프레이 라이알트리스(Ryaltris) 출시를 위한 최종 국가별 판매 승인 신청 절차를 마무리하고 있다고 발표했습니다. 글렌마크는 라이얼트리스가 12세 이상 알레르기 비염 환자의 1차 치료제로 유럽에서 승인되었다고 발표했습니다. 라이얼트리스는 12세 이상 성인 및 소아의 계절성 및 만성 알레르기 비염 증상 치료에 사용됩니다. 이 약은 코막힘, 콧물, 코 가려움, 재채기, 눈 가려움, 충혈 및 눈물 등 알레르기 비염 증상을 완화합니다.
코로나19 영향 분석
이비인후과 연구팀이 실시한 연구에 따르면, 많은 알레르기 비염 환자들이 코로나19 봉쇄 기간 동안 실내 알레르겐 노출 증가와 면역요법 중단으로 인해 증상이 악화된 것으로 나타났습니다. 이 연구는 알레르겐 회피, 약물 치료, 알레르겐 면역요법(SIT)을 통한 장기적인 관리, 1차 예방 및 조절의 중요성을 강조합니다. 환경적 요인은 알레르기 비염 발병기전에 매우 중요하며, 면역요법은 질병의 자연 경과를 변화시키는 유일한 치료법입니다.

시장 세분화
약물 종류별
• 항히스타민제
• 스테로이드제
• 충혈 완화제
• 알레르겐 면역요법 제제
• 기타
투여 경로별
• 경구
• 비강 투여
• 근육 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 업체로는 AdenHealthcare, Niprojmipharma, Krosyl Pharma, Sanis Health Inc, Hanmi Pharma, Johnson & Johnson Consumer Inc, Bristol Laboratories Ltd, GSK, Nutra 등이 있습니다. Respiro, Bayer Canada 등을 포함한 여러 기업.
주요 동향
 2023년 7월, 중요한 미충족 의료 수요를 해결하는 치료제 개발에 주력하는 기업인 Altamira Therapeutics Ltd는 Pharma Nordic AS와 공기 중 알레르겐으로부터 보호하는 비강 스프레이인 Bentrio의 노르웨이 및 기타 스칸디나비아 국가에서의 마케팅 및 유통에 대한 독점 계약을 체결했다고 발표했습니다. 이 협력 계약을 통해 Pharma Nordic은 2024년 1분기부터 노르웨이에서 Bentrio를 판매 및 상용화할 수 있으며, 특정 목표 달성 시 스웨덴, 핀란드, 덴마크에서도 판매 및 상용화할 수 있습니다.
보고서 구매 이유

• 약물 종류, 투여 경로, 유통 채널 및 지역별 전 세계 만성 알레르기 비염 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 만성 알레르기 비염 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 만성 알레르기 비염 치료제 시장 보고서는 약 61개의 표, 58개의 그림, 187페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Perennial Allergic Rhinitis Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Perennial rhinitis can be defined clinically as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhoea, occurring for an hour or more on most days throughout the year. Rhinitis is commonly managed by both primary and secondary care physicians. Although most cases can be diagnosed and treated in primary care, referral to secondary care is often necessary when patients do not respond to treatment or other diagnoses are suspected.
Market Dynamics: Drivers and Restraints
Rise in the prevalence of allergic rhinitis
A global disease allergic rhinitis (AR) affects a huge proportion of people around the world. Allergic rhinitis is diagnosed with a group of symptoms affecting the nose. These symptoms occur when people breathe in something they are allergic to, such as dust, animal dander or pollen.
Changes in genetic factors are unlikely to be the underlying cause of the rise in allergic diseases since the increases in allergic rhinitis and asthma occurred relatively rapidly. Instead, multiple environmental factors may have played a role. These include improvements in hygiene, eradication of most parasitic worm infections, changes in home heating and ventilation, and a decline in physical activity and alterations in diet due to lifestyle changes.
The rise in the prevalence of allergic rhinitis is one of the significant key factors that drive the saline spray market during the forecast period. For instance, according to the article published in the National Library of Medicine 2023, the prevalence of AR cases ranged from 1.83 to 9.23% between 2017 and 2022. There was a significant drop of 21.38 to 70.22% between the pre- and post-COVID-19 pandemic. Males were more prevalent in the 6 to 18-year-olds than females. Thus, the above factors help to drive market growth during the forecast period.
Furthermore, ongoing extensive R&D activities for the development of more effective products and formulations, changes in environmental conditions, increasing pollution, rising number of patients, and changes in lifestyle are proving the major driving factors for the perennial allergic rhinitis market.
Market Dynamics: Restraint
Allergic rhinitis is a serious health condition that can lead to sleep disturbances, fatigue, irritability, depression, and difficulty paying attention. If left untreated, it can become chronic and lead to complications such as nasal inflammation, sinusitis, otitis media, sleep apnea, upper respiratory tract infection, dental problems, and eustachian tube dysfunction. It is also linked to increased chances of developing asthma, flares, worsening symptoms, and difficult-to-control asthma in those with existing asthma.
Segment Analysis
The global perennial allergic rhinitis drugs market is segmented based on drug class, route of administration, distribution channel and region.
The anti-histamines segment from the drug class segment accounted for approximately 41.7% of the perennial allergic rhinitis drugs market share
The anti-histamines segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Antihistamines are a pharmaceutical class of drugs that act to treat histamine-mediated conditions. There are two main classes of histamine receptors: H-1 receptors and H-2 receptors. Antihistamine drugs that bind to H-1 receptors are generally used to treat allergies and allergic rhinitis.
For instance, in June 2021, the U.S. Food and Drug Administration approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.
Geographical Analysis
Europe accounted for approximately 31.4% of the market share in 2022
Europe is estimated to hold about 31.4% of the total market share throughout the forecast period, owing to the rise in the prevalence of perennial allergic rhinitis, novel drug launches, rise in research and development, well-established market players, collaborations and acquisition with key players and others help this region to be having highest market share during the forecast period.
For instance, in April 2021, Glenmark Pharma stated that it is concluding the final, national phase of its marketing approval application process to launch its nasal spray Ryaltris in 17 countries in the European Union (EU). Glenmark said Ryaltris is now approved in Europe for the first-line treatment of allergic rhinitis in patients over 12 years of age. Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
COVID-19 Impact Analysis
A study conducted by an investigative otolaryngology group they found that many patients with allergic rhinitis symptoms worsened due to increased exposure to indoor allergens and discontinuation of immunotherapy during COVID-19 lockdowns. The study emphasizes the importance of long-term management, primary prevention, and control through allergen avoidance measures, pharmacotherapy, and allergen-SIT. Environmental factors are critical in AR pathogenesis, and immunotherapy remains the only treatment that alters the disease's natural history.
Market Segmentation
By Drug Class
• Anti Histamines
• Steroids
• Decongestants
• Allergen Immunotherapy formulations
• Others
By Route of Administration
• Oral
• Nasal
• Intramuscular
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include AdenHealthcare, Niprojmipharma, Krosyl Pharma, Sanis Health Inc, Hanmi Pharma, Johnson & Johnson Consumer Inc, Bristol Laboratories Ltd, GSK, Nutra Respiro, Bayer Canada and among others.
Key Developments
 In July 2023, Altamira Therapeutics Ltd, a company dedicated to developing therapeutics that address important unmet medical needs, stated that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.
Why Purchase the Report?
• To visualize the global perennial allergic rhinitis drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of perennial allergic rhinitis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global perennial allergic rhinitis drugs market report would provide approximately 61 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of allergic rhinitis
4.1.1.2. Ongoing extensive R&D activities for the development of more effective products and formulations
4.1.2. Restraints
4.1.2.1. Complications associated with the perennial allergic rhinitis drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Anti Histamines *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Steroids
7.4. Decongestants
7.5. Allergen Immunotherapy formulations
7.6. Others
8. By Route of administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Nasal
8.4. Intramuscular
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. AdenHealthcare*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Niprojmipharma
12.3. Krosyl Pharma
12.4. Sanis Health Inc
12.5. Hanmi Pharma
12.6. Johnson & Johnson Consumer Inc.
12.7. Bristol Laboratories Ltd
12.8. GSK
12.9. Nutra Respiro
12.10. Bayer Canada
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

AdenHealthcare, 4.	Key Developments, Niprojmipharma, Krosyl Pharma, Sanis Health Inc, Hanmi Pharma, Johnson & Johnson Consumer Inc., Bristol Laboratories Ltd, GSK, Nutra Respiro, Bayer Canada

표 목록 (Tables)

List of Tables

Table 1 Global Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Perennial Allergic Rhinitis Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 7 Global Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Perennial Allergic Rhinitis Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Perennial Allergic Rhinitis Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 14 North America Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Perennial Allergic Rhinitis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 South America Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Perennial Allergic Rhinitis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 Europe Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Perennial Allergic Rhinitis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 AdenHealthcare: Overview

Table 33 AdenHealthcare: Product Portfolio

Table 34 AdenHealthcare: Key Developments

Table 35 Niprojmipharma: Overview

Table 36 Niprojmipharma: Product Portfolio

Table 37 Niprojmipharma: Key Developments

Table 38 Krosyl Pharma: Overview

Table 39 Krosyl Pharma: Product Portfolio

Table 40 Krosyl Pharma: Key Developments

Table 41 Sanis Health Inc: Overview

Table 42 Sanis Health Inc: Product Portfolio

Table 43 Sanis Health Inc: Key Developments

Table 44 Hanmi Pharma: Overview

Table 45 Hanmi Pharma: Product Portfolio

Table 46 Hanmi Pharma: Key Developments

Table 47 Johnson & Johnson Consumer Inc.: Overview

Table 48 Johnson & Johnson Consumer Inc.: Product Portfolio

Table 49 Johnson & Johnson Consumer Inc.: Key Developments

Table 50 Bristol Laboratories Ltd: Overview

Table 51 Bristol Laboratories Ltd: Product Portfolio

Table 52 Bristol Laboratories Ltd: Key Developments

Table 53 GSK : Overview

Table 54 GSK : Product Portfolio

Table 55 GSK : Key Developments

Table 56 Nutra Respiro: Overview

Table 57 Nutra Respiro: Product Portfolio

Table 58 Nutra Respiro: Key Developments

Table 59 Bayer Canada: Overview

Table 60 Bayer Canada: Product Portfolio

Table 61 Bayer Canada: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Perennial Allergic Rhinitis Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Perennial Allergic Rhinitis Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Anti Histamines Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 8 Steroids Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Decongestants Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Allergen Immunotherapy formulations Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 11 Others Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Global Perennial Allergic Rhinitis Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Oral Route of Administration in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Nasal Route of Administration in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 15 Intramuscular Route of Administration in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 16 Global Perennial Allergic Rhinitis Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Global Perennial Allergic Rhinitis Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 South America Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 26 North America Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 North America Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 28 North America Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Perennial Allergic Rhinitis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 32 South America Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 South America Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Perennial Allergic Rhinitis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 Europe Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Perennial Allergic Rhinitis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 43 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Perennial Allergic Rhinitis Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 48 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Perennial Allergic Rhinitis Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 AdenHealthcare: Financials

Figure 51 Niprojmipharma: Financials

Figure 52 Krosyl Pharma: Financials

Figure 53 Sanis Health Inc: Financials

Figure 54 Hanmi Pharma: Financials

Figure 55 Johnson & Johnson Consumer Inc.: Financials

Figure 56 Bristol Laboratories Ltd: Financials

Figure 57 GSK : Financials

Figure 58 Nutra Respiro: Financials

Figure 59 Bayer Canada: Financials

세계 만성 알레르기 비염 시장 – 2023-2030

Global Perennial Allergic Rhinitis Market - 2023-2030